A total of 195 DNA samples were analyzed by LH-PCR. Peaks 340 to 375 bp long were the most informative, in all the LH-PCR profiles. PCoA based on LH-PCR profiles distinguished between intravaginal microbiota collected from BV and healthy women in Group 3 [Supplementary Figure 1] . Groups 0 and 4 were indistinguishable from each other in the PCoA plot, and both distinct from Group 3, as seen in our previous high-throughput sequencing study. [4] Clinically, the intravaginal microbiota at D7 returned to normal after metronidazole treatment. The PCoA distribution of Group 1 samples (cured at D7) was distinct from that of Group 0 (samples taken at D0) and overlapped with that of Group 3 (cured at D30). The distributions of Groups 1 and 2 were distinct from Group 0 but partially overlapped with Group 3.
for each group of samples to show whether microbial patterns could predict the prognosis [ Figure 1 ]. Groups 0 and 4 showed greater relative peak areas for several fragments, than Groups 1, 2, and 3, suggesting that bacterial diversity is richer in BV infection than under normal conditions. Ten of the 14 fragments (341 bp, 343 bp, 345 bp, 347 bp, 349 bp, 353 bp, 354 bp, 361 bp, 368 bp, and 375 bp) come from genera (i.e., respectively, Ureaplasma or Mycoplasma, Sneathia, Atopobium, Gardnerella, Mobiluncus, Prevotella, Actinomyces, Anaerococcus, and Megasphaera) that include pathogenic bacteria that cause the clinical symptoms of BV. Lactobacillus (the 375 bp fragment) is the predominant genus of vaginal microbiota in healthy women. [7] Groups 0 and 4 (from women with clinical symptoms of BV) show relative increases of pathogenic bacteria and decreases of Lactobacillus. This suggests that the LH-PCR profiles here are sufficient to diagnose BV.
In conclusion, LH-PCR can provide useful information on patients' vaginal microbiome, allowing physicians to adjust therapeutic regimes and improve the rate of successful treatment of BV. The LH-PCR peaks at 341 bp, 343 bp, 345 bp, 347 bp, 349 bp, 353 bp, 354 bp, 361 bp, 368 bp, and 375 bp are potential indicators of BV and may be used in future as diagnostic and prognostic markers.
Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.

Figure 1:
Length-heterogeneity profiles of the relative diversity and abundance of the predominant bacterial fragments at three time points (days 0, 7, and 30). Group 0 is the disease condition at day 0; Group 1 is the cured group at day 7; Group 2 is the failed group at day 7; Group 3 is the cured group at day 30; and Group 4 is the failed group at day 30. LH-PCR profiles show two distinct patterns: the untreated/failed groups and the cured groups. Groups 0 and 4 showed greater relative peak areas for several fragments than Groups 1, 2, and 3, suggesting that bacterial diversity is richer in bacterial vaginosis infection than in normal conditions. LH-PCR: Length-heterogeneity polymerase chain reaction.
Supplementary Figure 1:
Principal component analysis of the Bray-Curtis dissimilarity among all samples at day 0, day 7, and day 30. Group 0 is the disease condition at day 0; Group 1 is the cured group at day 7; Group 2 is the failed group at day 7; Group 3 is the cured group at day 30; and Group 4 is the failed group at day 30. The vaginal microbial community showed two discrete patterns: the untreated/failed groups and the cured groups. IPCA: Independent principal component analysis.
